{"id":27138,"date":"2017-09-01T15:52:42","date_gmt":"2017-09-01T15:52:42","guid":{"rendered":"https:\/\/web.uri.edu\/pharmacy\/?p=27138"},"modified":"2017-09-01T15:52:42","modified_gmt":"2017-09-01T15:52:42","slug":"prescribe-to-prevent","status":"publish","type":"post","link":"https:\/\/web.uri.edu\/pharmacy\/2017\/09\/01\/prescribe-to-prevent\/","title":{"rendered":"Prescribe to Prevent"},"content":{"rendered":"<h1><a title=\"Continuing Professional Development\" href=\"https:\/\/web.uri.edu\/pharmacy\/cpd\/\">Continuing Professional Development<\/a><\/h1>\n<h4><a title=\"Office of Continuing Professional Development\" href=\"https:\/\/web.uri.edu\/pharmacy\/cpd\/\">Office of Continuing Professional Development<\/a><\/h4>\n<h2>Home Study Program<br \/>\nPrescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists<\/h2>\n<div class=\"buttoncol\" style=\"width: 250px\"><a href=\"https:\/\/www.uripharmacycpd.org\/user\/login\">Register here<\/a><\/div>\n<h3>Activity Overview<\/h3>\n<p><strong>Prescribe to Prevent:\u00a0<\/strong><em>Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists<\/em>\u00a0is an online educational program for prescribers, pharmacists, and other healthcare providers that will help you prevent overdoses among your patients and their social networks. Through the program you will see videos of patient-pharmacist-prescriber encounters that model how to provide a patient overdose education and a naloxone rescue kit. The program also includes very brief instructional videos for the available naloxone rescue kit formulations designed for you to use with your patients.<br \/>\nThe online program located at http:\/\/www.opioidprescribing.com\/naloxone_module_1-landing\u00a0includes resources to help health care providers educate their patients to reduce overdose risk and provide naloxone rescue kits to\u00a0patients and their social networks. Upon completion of the online program at http:\/\/www.opioidprescribing.com\/naloxone_module_1-landing, pharmacists who wish to obtain CE credit should take the post-test below.<\/p>\n<h3>Presentation<\/h3>\n<p><strong>Presentation Materials<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.uripharmacycpd.org\/static\/exams\/1595\/naloxone_slides_20160909.pdf\"><strong>PrescribetoPreventSlides<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.uripharmacycpd.org\/static\/exams\/1595\/naloxone_transcript_20160909.pdf\"><strong>PrescribetoPreventTranscript<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.uripharmacycpd.org\/static\/exams\/1595\/naloxone_prescriptions_20160909.pdf\"><strong>Sample Prescriptions<\/strong><\/a><\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/www.uripharmacycpd.org\/student\/exam\/1595\/take\">Take Post-Test<\/a><\/strong><\/p>\n<h3>Activity Information<\/h3>\n<p><strong>Target Audience<\/strong><br \/>\nPharmacists, physicians, nurse practitioners, physician assistants, and nurses. All professions will find value in this training; however,\u00a0completing the post-test on this site, only offers CE credit for pharmacists.<br \/>\n<strong>Learning Objectives<\/strong><\/p>\n<ol>\n<li>Explain the epidemiology of overdose;<\/li>\n<li>Explain the rational for and scope of overdose prevention education and naloxone rescue kit distribution;<\/li>\n<li>Incorporate overdose prevention education and naloxone rescue kits into medical and pharmacy practice by a) educating patients about overdose risk reduction and b) furnishing naloxone rescue kits; and<\/li>\n<li>Explain the legal and policy environment regarding furnishing naloxone rescue kits.<\/li>\n<\/ol>\n<h3>Activity Faculty<\/h3>\n<p><strong>Faculty Disclosure Statement<br \/>\n<\/strong><br \/>\nBoston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.<br \/>\n<strong>Faculty and Disclosure Information<\/strong><br \/>\n<strong>Daniel P. Alford, MD, MPH, FACP (Course Co-Director)<br \/>\n<\/strong>Associate Professor of Medicine<br \/>\nBoston University School of Medicine<br \/>\nBoston Medical Center<br \/>\n<a href=\"mailto:dan.alford@bmc.org\">dan.alford@bmc.org<\/a><br \/>\n<em>Faculty member has nothing to disclose with regards to commercial support.\u00a0Faculty member indicates that he does not plan to discuss unlabeled\/investigational uses of a commercial product.<\/em><br \/>\n<strong>Alexander Y. Walley, MD, MSc\u00a0(Course Co-Director)<br \/>\n<\/strong>Assistant Professor of Medicine<br \/>\nCo-Program Director, Addiction Medicine Fellowship Program Program<br \/>\nDirector, Fellow Immersion Training Program<br \/>\nBoston University School of Medicine and Boston Medical Center<br \/>\n<em>Faculty member is a consultant for Social Sciences Innovation Research, Inc.\u00a0Faculty member indicates that he does plan to discuss unlabeled\/investigational uses of a commercial product.\u00a0 The intra-nasal delivery of naloxone is not approved by the FDA.<\/em><strong>\u00a0<\/strong><br \/>\n<strong>Jeffrey Bratberg, PharmD, BCPS<br \/>\n<\/strong>Clinical Professor of Pharmacy<br \/>\nUniversity of Rhode Island College of Pharmacy<br \/>\nInfectious Disease Specialist<br \/>\nRoger Williams Medical Center, Providence, RI<br \/>\n<em>Faculty member is a consultant for and on the speakers bureau for Merck, and on the speakers bureau for Sanofi Pasteur.\u00a0Faculty member indicates that he does plan to discuss unlabeled\/ investigational uses of a commercial product.\u00a0 The intra-nasal delivery of naloxone is not approved by the FDA.<\/em><br \/>\n<strong>Corey Davis, JD, MSPH<br \/>\n<\/strong>Deputy Director<br \/>\nThe Network for Public Health Law<br \/>\n<em>Faculty member has nothing to disclose with regards to commercial support.\u00a0Faculty member indicates that he does plan to discuss unlabeled\/investigational uses of a commercial product.\u00a0 The intra-nasal delivery of naloxone is not approved by the FDA.<\/em><br \/>\n<strong>Ilana Hardesty<\/strong>, Program Operations Manager, and\u00a0<strong>Patti-Ann Collins<\/strong>, Lead Nurse Planner, Boston University School of Medicine CME Office, have nothing to disclose with regards to commercial support.<br \/>\n<strong>Traci Green, MD<\/strong>, and\u00a0<strong>Nkiruka Emeagwali, MD<\/strong>, Video Actors, have nothing to disclose with regards to commercial support.\u00a0 They do discuss unlabeled\/investigational uses of a commercial product.\u00a0 The intra-nasal delivery of naloxone is not approved by the FDA.<br \/>\n<strong>Hardware &amp; Software Requirements<\/strong><\/p>\n<h3><strong>Activity Support<\/strong><\/h3>\n<p>This program is provided by Boston University School of Medicine and is supported by an unrestricted educational grant from the Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services.<\/p>\n<h3>Accreditation Information<\/h3>\n<p>Accreditation Statement: The University of Rhode Island, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.<br \/>\nCredit Designation: This program will provide the participant with\u00a0<strong>1.25 Contact Hours (0.1 25 CEUs)<\/strong>\u00a0of continuing pharmacy education credit for completion of the home study and post-test. Participants will be able to print their statement of credit via the CPE Monitor after completing the post-test \u00a0following the activity.<br \/>\n<strong>Universal Activity Number (UAN): 0060-9999-14-062-H01-P.<\/strong><br \/>\nRelease Date: 10\/15\/2014<br \/>\nExpiration Date: 10\/15\/2017<br \/>\nActivity Type: This program is a knowledge-based continuing education activity.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Continuing Professional Development Office of Continuing Professional Development Home Study Program Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists Register here Activity Overview Prescribe to Prevent:\u00a0Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists\u00a0is an online educational program for prescribers, pharmacists, and other healthcare providers that will help you [&hellip;]<\/p>\n","protected":false},"author":581,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-27138","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/posts\/27138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/users\/581"}],"replies":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/comments?post=27138"}],"version-history":[{"count":0,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/posts\/27138\/revisions"}],"wp:attachment":[{"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/media?parent=27138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/categories?post=27138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/tags?post=27138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}